Cargando…

High throughput virtual screening reveals SARS-CoV-2 multi-target binding natural compounds to lead instant therapy for COVID-19 treatment

The present-day world is severely suffering from the recently emerged SARS-CoV-2. The lack of prescribed drugs for the deadly virus has stressed the likely need to identify novel inhibitors to alleviate and stop the pandemic. In the present high throughput virtual screening study, we used in silico...

Descripción completa

Detalles Bibliográficos
Autores principales: Naik, Biswajit, Gupta, Nidhi, Ojha, Rupal, Singh, Satyendra, Prajapati, Vijay Kumar, Prusty, Dhaneswar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7250083/
https://www.ncbi.nlm.nih.gov/pubmed/32470577
http://dx.doi.org/10.1016/j.ijbiomac.2020.05.184
_version_ 1783538707351994368
author Naik, Biswajit
Gupta, Nidhi
Ojha, Rupal
Singh, Satyendra
Prajapati, Vijay Kumar
Prusty, Dhaneswar
author_facet Naik, Biswajit
Gupta, Nidhi
Ojha, Rupal
Singh, Satyendra
Prajapati, Vijay Kumar
Prusty, Dhaneswar
author_sort Naik, Biswajit
collection PubMed
description The present-day world is severely suffering from the recently emerged SARS-CoV-2. The lack of prescribed drugs for the deadly virus has stressed the likely need to identify novel inhibitors to alleviate and stop the pandemic. In the present high throughput virtual screening study, we used in silico techniques like receptor-ligand docking, Molecular dynamic (MD), and ADME properties to screen natural compounds. It has been documented that many natural compounds display antiviral activities, including anti–SARS-CoV effect. The present study deals with compounds of Natural Product Activity and Species Source (NPASS) database with known biological activity that probably impedes the activity of six essential enzymes of the virus. Promising drug-like compounds were identified, demonstrating better docking score and binding energy for each druggable targets. After an extensive screening analysis, three novel multi-target natural compounds were predicted to subdue the activity of three/more major drug targets simultaneously. Concerning the utility of natural compounds in the formulation of many therapies, we propose these compounds as excellent lead candidates for the development of therapeutic drugs against SARS-CoV-2.
format Online
Article
Text
id pubmed-7250083
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-72500832020-05-27 High throughput virtual screening reveals SARS-CoV-2 multi-target binding natural compounds to lead instant therapy for COVID-19 treatment Naik, Biswajit Gupta, Nidhi Ojha, Rupal Singh, Satyendra Prajapati, Vijay Kumar Prusty, Dhaneswar Int J Biol Macromol Article The present-day world is severely suffering from the recently emerged SARS-CoV-2. The lack of prescribed drugs for the deadly virus has stressed the likely need to identify novel inhibitors to alleviate and stop the pandemic. In the present high throughput virtual screening study, we used in silico techniques like receptor-ligand docking, Molecular dynamic (MD), and ADME properties to screen natural compounds. It has been documented that many natural compounds display antiviral activities, including anti–SARS-CoV effect. The present study deals with compounds of Natural Product Activity and Species Source (NPASS) database with known biological activity that probably impedes the activity of six essential enzymes of the virus. Promising drug-like compounds were identified, demonstrating better docking score and binding energy for each druggable targets. After an extensive screening analysis, three novel multi-target natural compounds were predicted to subdue the activity of three/more major drug targets simultaneously. Concerning the utility of natural compounds in the formulation of many therapies, we propose these compounds as excellent lead candidates for the development of therapeutic drugs against SARS-CoV-2. Elsevier B.V. 2020-10-01 2020-05-26 /pmc/articles/PMC7250083/ /pubmed/32470577 http://dx.doi.org/10.1016/j.ijbiomac.2020.05.184 Text en © 2020 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Naik, Biswajit
Gupta, Nidhi
Ojha, Rupal
Singh, Satyendra
Prajapati, Vijay Kumar
Prusty, Dhaneswar
High throughput virtual screening reveals SARS-CoV-2 multi-target binding natural compounds to lead instant therapy for COVID-19 treatment
title High throughput virtual screening reveals SARS-CoV-2 multi-target binding natural compounds to lead instant therapy for COVID-19 treatment
title_full High throughput virtual screening reveals SARS-CoV-2 multi-target binding natural compounds to lead instant therapy for COVID-19 treatment
title_fullStr High throughput virtual screening reveals SARS-CoV-2 multi-target binding natural compounds to lead instant therapy for COVID-19 treatment
title_full_unstemmed High throughput virtual screening reveals SARS-CoV-2 multi-target binding natural compounds to lead instant therapy for COVID-19 treatment
title_short High throughput virtual screening reveals SARS-CoV-2 multi-target binding natural compounds to lead instant therapy for COVID-19 treatment
title_sort high throughput virtual screening reveals sars-cov-2 multi-target binding natural compounds to lead instant therapy for covid-19 treatment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7250083/
https://www.ncbi.nlm.nih.gov/pubmed/32470577
http://dx.doi.org/10.1016/j.ijbiomac.2020.05.184
work_keys_str_mv AT naikbiswajit highthroughputvirtualscreeningrevealssarscov2multitargetbindingnaturalcompoundstoleadinstanttherapyforcovid19treatment
AT guptanidhi highthroughputvirtualscreeningrevealssarscov2multitargetbindingnaturalcompoundstoleadinstanttherapyforcovid19treatment
AT ojharupal highthroughputvirtualscreeningrevealssarscov2multitargetbindingnaturalcompoundstoleadinstanttherapyforcovid19treatment
AT singhsatyendra highthroughputvirtualscreeningrevealssarscov2multitargetbindingnaturalcompoundstoleadinstanttherapyforcovid19treatment
AT prajapativijaykumar highthroughputvirtualscreeningrevealssarscov2multitargetbindingnaturalcompoundstoleadinstanttherapyforcovid19treatment
AT prustydhaneswar highthroughputvirtualscreeningrevealssarscov2multitargetbindingnaturalcompoundstoleadinstanttherapyforcovid19treatment